Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A28, 15, and 16 (R456H, P42R, and R377Q)

P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450...

Full description

Saved in:
Bibliographic Details
Published inBiomolecules & therapeutics Vol. 23; no. 2; pp. 189 - 194
Main Authors Lim, Young-Ran, Kim, In-Hyeok, Han, Songhee, Park, Hyoung-Goo, Ko, Mi-Jung, Chun, Young-Jin, Yun, Chul-Ho, Kim, Donghak
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Society of Applied Pharmacology 01.03.2015
한국응용약물학회
Subjects
Online AccessGet full text
ISSN2005-4483
1976-9148
1976-9148
2005-4483
DOI10.4062/biomolther.2015.009

Cover

Abstract P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.
AbstractList P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.
P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (kcat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (kcat/Km) increased up to 2.5 fold with a slight increase of its Km value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.
P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.
P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterizethe functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P4501A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes wereexpressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450holoenzyme with an expression level of ~ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however theexpression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P4501A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (kcat)in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis,the overall catalytic efficiency (kcat/Km) increased up to 2.5 fold with a slight increase of its Km value. This study indicated that thesubstitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reductionof P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefullyexamined in terms of the metabolism of many clinical drugs and environmental chemicals. KCI Citation Count: 4
Author Kim, In-Hyeok
Lim, Young-Ran
Ko, Mi-Jung
Park, Hyoung-Goo
Han, Songhee
Yun, Chul-Ho
Kim, Donghak
Chun, Young-Jin
AuthorAffiliation 3 School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea
2 College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea
1 Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
AuthorAffiliation_xml – name: 3 School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea
– name: 1 Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– name: 2 College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea
Author_xml – sequence: 1
  givenname: Young-Ran
  surname: Lim
  fullname: Lim, Young-Ran
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– sequence: 2
  givenname: In-Hyeok
  surname: Kim
  fullname: Kim, In-Hyeok
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– sequence: 3
  givenname: Songhee
  surname: Han
  fullname: Han, Songhee
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– sequence: 4
  givenname: Hyoung-Goo
  surname: Park
  fullname: Park, Hyoung-Goo
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– sequence: 5
  givenname: Mi-Jung
  surname: Ko
  fullname: Ko, Mi-Jung
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
– sequence: 6
  givenname: Young-Jin
  surname: Chun
  fullname: Chun, Young-Jin
  organization: College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea
– sequence: 7
  givenname: Chul-Ho
  surname: Yun
  fullname: Yun, Chul-Ho
  organization: School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea
– sequence: 8
  givenname: Donghak
  surname: Kim
  fullname: Kim, Donghak
  organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25767688$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001965494$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqNUk1v1DAUtFAR3RZ-ARLysUibxR8vTnxBWq3oh1QJWApXy_E6XVPH3joJaP99EwJd4IA4Pckz45k39gk6CjFYhF5SsgAi2JvKxSb6bmvTghGaLwiRT9CMykJkkkJ5hGaMkDwDKPkxOmnbr4SIgubiGTpmeSEKUZYzFM_7YDoXg_b4k7sNrnZGB2NxrPFq30WzTbGx-APkBNMlw0vvrXcGf9HJ6dC180eonGOaz7EOG0wFPltDLi5HlK2nwzUvio-vn6OntfatffFznqLP5-9uVpfZ9fuLq9XyOjNApcyMKAUHKziVIrfaABRVreWmqktTA8hCc55ryRmnWhtWV8LwCopNJcpCggV-is6me0Oq1Z1xKmr3Y95GdZfUcn1zpQYjAWSgwkTtw07vv2vv1S65Rqe9okSNVatD1WqsWg1VD7K3k2zXV43dGBu6pA_S0e9PJLjt4P5NAc-BM3qIuEvxvrdtpxrXGuu9Djb2raJCACMlyDHiq9-9Hk1-veNA4BPBpNi2ydb_uYL8S2Vcp8ffMAR2_p_aB1uQwpA
CitedBy_id crossref_primary_10_1016_j_dmpk_2016_09_003
crossref_primary_10_1080_14756366_2023_2187327
crossref_primary_10_1016_j_dmpk_2017_10_004
crossref_primary_10_1021_acsami_4c08329
crossref_primary_10_1016_j_bbrc_2016_11_131
crossref_primary_10_1038_s41598_021_83696_x
Cites_doi 10.1016/S0378-1119(98)00567-8
10.1016/j.abb.2003.11.019
10.1007/s12272-011-1103-2
10.1016/j.taap.2003.11.030
10.5487/TR.2014.30.1.033
10.2133/dmpk.20.24
10.1021/bi000869u
10.1038/clpt.1991.176
10.4062/biomolther.2013.086
10.1124/mi.3.4.194
10.1016/S0021-9258(18)41713-9
10.4062/biomolther.2009.17.2.156
10.1126/science.8342039
10.1248/bpb.35.394
10.1074/jbc.M508171200
10.1074/jbc.M611692200
10.1124/dmd.105.005819
10.1146/annurev.pharmtox.45.120403.100010
ContentType Journal Article
Copyright Copyright © 2015 The Korean Society of Applied Pharmacology 2015
Copyright_xml – notice: Copyright © 2015 The Korean Society of Applied Pharmacology 2015
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
DOI 10.4062/biomolther.2015.009
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
EISSN 1976-9148
2005-4483
EndPage 194
ExternalDocumentID oai_kci_go_kr_ARTI_199640
oai:pubmedcentral.nih.gov:4354321
PMC4354321
25767688
10_4062_biomolther_2015_009
Genre Journal Article
GroupedDBID ---
23N
5-W
5GY
8JR
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
F5P
HYE
HZB
JDI
KQ8
M48
OK1
PGMZT
RPM
NPM
7X8
5PM
ADTOC
UNPAY
.UV
ACYCR
ID FETCH-LOGICAL-c4199-c68634e631965eac447bfa9dbf8cf4497a335a93231aac2fb6c3b47db68794e43
IEDL.DBID M48
ISSN 2005-4483
1976-9148
IngestDate Tue Nov 21 21:47:39 EST 2023
Sun Oct 26 03:40:24 EDT 2025
Tue Sep 30 16:47:46 EDT 2025
Fri Jul 11 13:22:23 EDT 2025
Thu Apr 03 07:07:18 EDT 2025
Tue Jul 01 04:58:28 EDT 2025
Thu Apr 24 23:10:03 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 2
Keywords Allelic variants
Methoxyresorufin
Phenacetin
P450 1A2
Polymorphism
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4199-c68634e631965eac447bfa9dbf8cf4497a335a93231aac2fb6c3b47db68794e43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000363.2015.23.2.008
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2015.009
PMID 25767688
PQID 1664208490
PQPubID 23479
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_199640
unpaywall_primary_10_4062_biomolther_2015_009
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4354321
proquest_miscellaneous_1664208490
pubmed_primary_25767688
crossref_primary_10_4062_biomolther_2015_009
crossref_citationtrail_10_4062_biomolther_2015_009
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-03-01
PublicationDateYYYYMMDD 2015-03-01
PublicationDate_xml – month: 03
  year: 2015
  text: 2015-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Biomolecules & therapeutics
PublicationTitleAlternate Biomol Ther (Seoul)
PublicationYear 2015
Publisher The Korean Society of Applied Pharmacology
한국응용약물학회
Publisher_xml – name: The Korean Society of Applied Pharmacology
– name: 한국응용약물학회
References (OOOMB4_2015_v23n2_189_017) 2005; 20
(OOOMB4_2015_v23n2_189_013) 1993; 261
(OOOMB4_2015_v23n2_189_019) 2004; 422
(OOOMB4_2015_v23n2_189_015) 2007; 282
(OOOMB4_2015_v23n2_189_001) 1992; 267
(OOOMB4_2015_v23n2_189_009) 2005; 280
(OOOMB4_2015_v23n2_189_010) 2011; 34
(OOOMB4_2015_v23n2_189_016) 1978; 1
(OOOMB4_2015_v23n2_189_003) 2003; 3
(OOOMB4_2015_v23n2_189_008) 2005; 45
(OOOMB4_2015_v23n2_189_004) 2012; 35
(OOOMB4_2015_v23n2_189_011) 1999; 226
(OOOMB4_2015_v23n2_189_014) 2005; 33
(OOOMB4_2015_v23n2_189_006) 1991; 50
(OOOMB4_2015_v23n2_189_007) 2004; 199
(OOOMB4_2015_v23n2_189_012) 2014; 30
(OOOMB4_2015_v23n2_189_002) 2013; 21
(OOOMB4_2015_v23n2_189_005) 2009; 17
(OOOMB4_2015_v23n2_189_018) 2000; 39
1429608 - J Biol Chem. 1992 Nov 5;267(31):22587-94
16174806 - Drug Metab Dispos. 2005 Dec;33(12):1905-10
16207711 - J Biol Chem. 2005 Dec 2;280(48):40319-27
8342039 - Science. 1993 Aug 6;261(5122):731-6
1934864 - Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508-19
15364546 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):305-15
15770072 - Drug Metab Pharmacokinet. 2005 Feb;20(1):24-33
24404341 - Biomol Ther (Seoul). 2013 Nov;21(6):487-92
76883 - Lancet. 1978 Apr 29;1(8070):943-4
24795797 - Toxicol Res. 2014 Mar;30(1):33-8
9931507 - Gene. 1999 Jan 21;226(2):327-38
17311915 - J Biol Chem. 2007 May 11;282(19):14348-55
10985777 - Biochemistry. 2000 Sep 19;39(37):11319-29
22382327 - Biol Pharm Bull. 2012;35(3):394-9
14725854 - Arch Biochem Biophys. 2004 Feb 1;422(1):23-30
22139682 - Arch Pharm Res. 2011 Nov;34(11):1799-816
14993447 - Mol Interv. 2003 Jun;3(4):194-204
15822170 - Annu Rev Pharmacol Toxicol. 2005;45:27-49
References_xml – volume: 226
  start-page: 327
  year: 1999
  ident: OOOMB4_2015_v23n2_189_011
  publication-title: Gene
  doi: 10.1016/S0378-1119(98)00567-8
– volume: 422
  start-page: 23
  year: 2004
  ident: OOOMB4_2015_v23n2_189_019
  publication-title: Arch. Biochem. Biophys.
  doi: 10.1016/j.abb.2003.11.019
– volume: 34
  start-page: 1799
  year: 2011
  ident: OOOMB4_2015_v23n2_189_010
  publication-title: Arch. Pharm. Res.
  doi: 10.1007/s12272-011-1103-2
– volume: 199
  start-page: 305
  year: 2004
  ident: OOOMB4_2015_v23n2_189_007
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2003.11.030
– volume: 30
  start-page: 33
  year: 2014
  ident: OOOMB4_2015_v23n2_189_012
  publication-title: Toxicol. Res.
  doi: 10.5487/TR.2014.30.1.033
– volume: 20
  start-page: 24
  year: 2005
  ident: OOOMB4_2015_v23n2_189_017
  publication-title: Drug Metab. Pharmacokinet.
  doi: 10.2133/dmpk.20.24
– volume: 39
  start-page: 11319
  year: 2000
  ident: OOOMB4_2015_v23n2_189_018
  publication-title: Biochemistry
  doi: 10.1021/bi000869u
– volume: 50
  start-page: 508
  year: 1991
  ident: OOOMB4_2015_v23n2_189_006
  publication-title: Clin. Pharmacol. Ther.
  doi: 10.1038/clpt.1991.176
– volume: 21
  start-page: 487
  year: 2013
  ident: OOOMB4_2015_v23n2_189_002
  publication-title: Biomol. Ther.
  doi: 10.4062/biomolther.2013.086
– volume: 3
  start-page: 194
  year: 2003
  ident: OOOMB4_2015_v23n2_189_003
  publication-title: Mol. Interv.
  doi: 10.1124/mi.3.4.194
– volume: 267
  start-page: 22587
  year: 1992
  ident: OOOMB4_2015_v23n2_189_001
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(18)41713-9
– volume: 17
  start-page: 156
  year: 2009
  ident: OOOMB4_2015_v23n2_189_005
  publication-title: Biomol. Ther.
  doi: 10.4062/biomolther.2009.17.2.156
– volume: 261
  start-page: 731
  year: 1993
  ident: OOOMB4_2015_v23n2_189_013
  publication-title: Science
  doi: 10.1126/science.8342039
– volume: 35
  start-page: 394
  year: 2012
  ident: OOOMB4_2015_v23n2_189_004
  publication-title: Biol. Pharm. Bull.
  doi: 10.1248/bpb.35.394
– volume: 280
  start-page: 40319
  year: 2005
  ident: OOOMB4_2015_v23n2_189_009
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M508171200
– volume: 282
  start-page: 14348
  year: 2007
  ident: OOOMB4_2015_v23n2_189_015
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M611692200
– volume: 1
  start-page: 943
  year: 1978
  ident: OOOMB4_2015_v23n2_189_016
  publication-title: Lancet
– volume: 33
  start-page: 1905
  year: 2005
  ident: OOOMB4_2015_v23n2_189_014
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.105.005819
– volume: 45
  start-page: 27
  year: 2005
  ident: OOOMB4_2015_v23n2_189_008
  publication-title: Annu. Rev. Pharmacol. Toxicol.
  doi: 10.1146/annurev.pharmtox.45.120403.100010
– reference: 15822170 - Annu Rev Pharmacol Toxicol. 2005;45:27-49
– reference: 76883 - Lancet. 1978 Apr 29;1(8070):943-4
– reference: 17311915 - J Biol Chem. 2007 May 11;282(19):14348-55
– reference: 14725854 - Arch Biochem Biophys. 2004 Feb 1;422(1):23-30
– reference: 15770072 - Drug Metab Pharmacokinet. 2005 Feb;20(1):24-33
– reference: 24795797 - Toxicol Res. 2014 Mar;30(1):33-8
– reference: 22382327 - Biol Pharm Bull. 2012;35(3):394-9
– reference: 8342039 - Science. 1993 Aug 6;261(5122):731-6
– reference: 1429608 - J Biol Chem. 1992 Nov 5;267(31):22587-94
– reference: 15364546 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):305-15
– reference: 24404341 - Biomol Ther (Seoul). 2013 Nov;21(6):487-92
– reference: 22139682 - Arch Pharm Res. 2011 Nov;34(11):1799-816
– reference: 10985777 - Biochemistry. 2000 Sep 19;39(37):11319-29
– reference: 1934864 - Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508-19
– reference: 16174806 - Drug Metab Dispos. 2005 Dec;33(12):1905-10
– reference: 14993447 - Mol Interv. 2003 Jun;3(4):194-204
– reference: 16207711 - J Biol Chem. 2005 Dec 2;280(48):40319-27
– reference: 9931507 - Gene. 1999 Jan 21;226(2):327-38
SSID ssj0067156
Score 1.9879814
Snippet P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450...
P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450...
SourceID nrf
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 189
SubjectTerms Original
약학
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdY9wAvMMRXx4eMxANIzUjiixM_VtOqgsQ0CkXjybKdeKsaJVPXahp_PXdJl60aoPGUKL7E8vnOd2dffsfYO5clsQpDG8RCyACEKQKq5hAYwBAoUWBzS4Hil0M5nsLn4-T4GibnxvE9Wpr4I_2DXpfkClEWFm1_qC22LRP0u3tse3p4NPzZHBunErW2KZXVQGtizCFaiKG_fWXDDG1VC_8nD_N2ouT9VXVmLi9MWd6wQqNHbTmj8wa8kJJP5nurpd1zv25DO95hgDvs4doZ5cNWeh6ze0X1hNUjNHXtDiH_NjupKJeIRIPXnu9fLmt3SggH_AiSkEfDmA_Lsihnjv_AqJuSagZdUzbgUTLgpsp5JPn7CXpRY2qNJ-3DiUjTrx-esuno4Pv-OFiXZQgcREoFTmZSQCFJeRNctwFS643Krc-cB1CpESIx6BeKyBgXeyudsJDmVmao_AWIZ6xX1VXxgnEPCQCumUWuUEC8VJGDLPQqynzscyv6LL6aJe3WmOVUOqPUGLsQ__Q1_zTxTyP_-mzQvXTWQnb8m_wtTr-eu5kmqG26ntR6vtAYUHzSlKQNIdJcCYdG9aMzFVMV9epcR1JSggIopHneCkvXKcVyGM1lfZZuiFFHQP1ttlSz0wbiG51YEHHUZ0EncHcZy-5_0r9kD-i2zal7xXrLxap4jU7W0r5Za9dvprUeDA
  priority: 102
  providerName: Unpaywall
Title Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A28, 15, and 16 (R456H, P42R, and R377Q)
URI https://www.ncbi.nlm.nih.gov/pubmed/25767688
https://www.proquest.com/docview/1664208490
https://pubmed.ncbi.nlm.nih.gov/PMC4354321
http://doi.org/10.4062/biomolther.2015.009
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001965494
UnpaywallVersion submittedVersion
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biomolecules & Therapeutics, 2015, 23(2), , pp.189-194
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1976-9148
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067156
  issn: 1976-9148
  databaseCode: KQ8
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1976-9148
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067156
  issn: 1976-9148
  databaseCode: DIK
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 1976-9148
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067156
  issn: 1976-9148
  databaseCode: 5-W
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1976-9148
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0067156
  issn: 1976-9148
  databaseCode: RPM
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1976-9148
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0067156
  issn: 1976-9148
  databaseCode: M48
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELf28QAvCMRX-ZiMxANIzYjjixM_oWqiKkibRqFoPFm2E2_VomR0raD_PXdNmzExEOIpUnyJFf98vt_ZlzvGXvo8TXQcuyiRUkUgbRlRNYfIArpAqQZXOHIUD4_UaAIfTtKTLbapiroewMsbXTuqJzWZVfs_vi3fosIjf91Hc5S8oR_Vm4r4EoVq0R6J3ma7aKo01XI4hO5YQWViVc5VoA1GLYe8TUP0p5dQomCk41lbluXKam3Xs3ATIf09rvLWor6wy--2qn4xWsO77M6abfJBOz3usa2yvs-aIdqydguQf5qe1hQsRNjzJvCD5bzxZ5TCgB9DGnMxSPigqspq6vkXdKspaqbfNeV9LtI-t3XBheKvxkiTRtSajNubY5llH18_YJPhu88Ho2hddyHyILSOvMqVhFKRdqa4MANkLlhduJD7AKAzK2VqkfhJYa1PglNeOsgKp3LU7hLkQ7ZTN3X5mPEAKQAuimWhcQYEpYWHPA5a5CEJhZM9lmzG1fh1UnKqjVEZdE4IF3OFiyFcDOLSY_3uoYs2J8ffxV8gYObcTw3l0qbraWPOZwY9hveGorAhRpkNnAb1iw5NbF02i0sjlKIIBNAo86iFt-t0Mzt6LLsGfCdA_V1vqadnqxzeyFJBJqLHom6K_Mu3PPnvnp6y2_SSNnzuGduZzxblc-RTc7e30pE9tjs5Oh58_QmY_hvQ
linkProvider Scholars Portal
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdY9wAvMMRXx4eMxANIzUjiixM_VtOqgsQ0CkXjybKdeKsaJVPXahp_PXdJl60aoPGUKL7E8vnOd2dffsfYO5clsQpDG8RCyACEKQKq5hAYwBAoUWBzS4Hil0M5nsLn4-T4GibnxvE9Wpr4I_2DXpfkClEWFm1_qC22LRP0u3tse3p4NPzZHBunErW2KZXVQGtizCFaiKG_fWXDDG1VC_8nD_N2ouT9VXVmLi9MWd6wQqNHbTmj8wa8kJJP5nurpd1zv25DO95hgDvs4doZ5cNWeh6ze0X1hNUjNHXtDiH_NjupKJeIRIPXnu9fLmt3SggH_AiSkEfDmA_Lsihnjv_AqJuSagZdUzbgUTLgpsp5JPn7CXpRY2qNJ-3DiUjTrx-esuno4Pv-OFiXZQgcREoFTmZSQCFJeRNctwFS643Krc-cB1CpESIx6BeKyBgXeyudsJDmVmao_AWIZ6xX1VXxgnEPCQCumUWuUEC8VJGDLPQqynzscyv6LL6aJe3WmOVUOqPUGLsQ__Q1_zTxTyP_-mzQvXTWQnb8m_wtTr-eu5kmqG26ntR6vtAYUHzSlKQNIdJcCYdG9aMzFVMV9epcR1JSggIopHneCkvXKcVyGM1lfZZuiFFHQP1ttlSz0wbiG51YEHHUZ0EncHcZy-5_0r9kD-i2zal7xXrLxap4jU7W0r5Za9dvprUeDA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Functional+Significance+of+Cytochrome+P450+1A2+Allelic+Variants%2C+P450+1A28%2C+15%2C+and+16+%28R456H%2C+P42R%2C+and+R377Q%29&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Lim%2C+Young-Ran&rft.au=Kim%2C+In-Hyeok&rft.au=Han%2C+Songhee&rft.au=Park%2C+Hyoung-Goo&rft.date=2015-03-01&rft.pub=The+Korean+Society+of+Applied+Pharmacology&rft.issn=1976-9148&rft.eissn=2005-4483&rft.volume=23&rft.issue=2&rft.spage=189&rft.epage=194&rft_id=info:doi/10.4062%2Fbiomolther.2015.009&rft_id=info%3Apmid%2F25767688&rft.externalDocID=PMC4354321
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-4483&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-4483&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-4483&client=summon